Sight Sciences, Inc.
NASDAQ:SGHTMedical - Devices
+$0.15 today
- Market cap
- $598.59M
- Beta
- 2.40
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$0.69
Volume 0.34M
Average 0.25M
SGHT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Sight Sciences, Inc.NASDAQ: SGHT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $103K fell 30.9% year over year, behind the -24.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.6% from the prior quarter. Over 3 fiscal years it compounded at -27.0% a year.
Context
- Depreciation & amortization amounted to 0.6% of revenue in FY2025, down 0.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -30.9% toward the trailing-twelve-month pace of -24.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 487K USD
- Year-over-year change
- -31.6%
- 4-year CAGR
- -20.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 487K | -31.6% |
| FY2024 | 2024-12-31 | 712K | +16.0% |
| FY2023 | 2023-12-31 | 614K | -51.0% |
| FY2022 | 2022-12-31 | 1.25M | +4.2% |
| FY2021 | 2021-12-31 | 1.2M | — |
Depreciation & Amortization vs competitors
How SGHT compares with its peers on the latest reported figures
- SGHT's LTM Mar 2026 depreciation & amortization of $441K is the lowest of the 7 companies compared; the peer median is $32.97M.
- Its year-over-year change of -24.4% is the lowest of 6, against a peer median of +20.3%.
- Depreciation & amortization amounts to 0.6% of revenue for SGHT, versus a peer median of 8.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.84B | +41.7% | +5.9% | 16.9% | |
| LTM Jun 2026 | $1.17B | -5.6% | -4.7% | 10.8% | |
| LTM Jun 2026 | $46.44M | +19.7% | +5.6% | 7.6% | |
| LTM Mar 2026 | $19.5M | +32.3% | +88.3% | 7.3% | |
| LTM Mar 2026 | $4.63M | +20.3% | +27.0% | 8.9% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $612K | — | — | — |
| LTM Mar 2026 | $441K | -24.4% | -27.0% | 0.6% | |
| Peer median (excluding SGHT) | $32.97M | +20.3% | +5.9% | 8.9% | |
Competitors are the stored peer set for SGHT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.96M | 71.33M | 81.06M | 79.87M | 77.36M |
| Cost of Revenue | 8.61M | 12.36M | 11.88M | 11.58M | 10.7M |
| Gross Profit | 40.35M | 58.97M | 69.18M | 68.29M | 66.67M |
| Gross Margin | 82.4% | 82.7% | 85.3% | 85.5% | 86.2% |
| Research & Development | 15.63M | 22.86M | 17.56M | 17.99M | 14.61M |
| Selling, General & Admin | 76.19M | 120.07M | 108.89M | 100.83M | 89.16M |
| Operating Expenses | 91.82M | 142.92M | 126.45M | 118.82M | 103.77M |
| Depreciation & Amortization | 1.2M | 1.25M | 614K | 712K | 487K |
| EBITDA | (57.21M) | (80.48M) | (49.42M) | (45.9M) | (32.79M) |
| EBITDA Margin | -116.8% | -112.8% | -61.0% | -57.5% | -42.4% |
| Operating Income | (51.48M) | (83.95M) | (57.27M) | (50.53M) | (37.1M) |
| Operating Margin | -105.2% | -117.7% | -70.7% | -63.3% | -48.0% |
| Interest Income | 0 | 0 | 0 | 0 | 3.97M |
| Interest Expense | 4.37M | 4.47M | 5.41M | 4.66M | 5.14M |
| Other Income / Expenses | (11.29M) | (2.24M) | 1.84M | (739K) | (1.32M) |
| Income Before Tax | (62.77M) | (86.2M) | (55.44M) | (51.27M) | (38.42M) |
| Pre-Tax Margin | -128.2% | -120.8% | -68.4% | -64.2% | -49.7% |
| Income Tax Expense | 188K | 47K | 110K | 236K | 10K |
| Net Income | (62.96M) | (86.24M) | (55.55M) | (51.51M) | (38.43M) |
| Net Margin | -128.6% | -120.9% | -68.5% | -64.5% | -49.7% |
| EPS (Basic) | (1.33) | (1.80) | (1.14) | (1.03) | (0.74) |
| EPS (Diluted) | (1.33) | (1.80) | (1.14) | (1.03) | (0.74) |
| Weighted Avg Shares | 47.5M | 47.85M | 48.63M | 50.13M | 52.15M |
| Weighted Avg Shares (Diluted) | 47.5M | 47.85M | 48.63M | 50.13M | 52.15M |
Sight Sciences, Inc.
NASDAQ:SGHT
Intrinsic Alpha fair value
Locked
Current Price
$10.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.